Results 241 to 250 of about 182,514 (265)
Some of the next articles are maybe not open access.
Cardiotoxicity of Immune Checkpoint Inhibitors
Current Treatment Options in Cardiovascular Medicine, 2019Immunotherapies, particularly immune checkpoint inhibitors (ICI), are revolutionary cancer therapies being increasingly applied to a broader range of cancers. Our understanding of the mechanism, epidemiology, diagnosis, and treatment of cardiotoxicity related to immunotherapies remains limited.
Lili, Zhang +8 more
openaire +2 more sources
Immune checkpoint inhibitor myocarditis
Current Opinion in Cardiology, 2019The purpose of this study is to summarize and highlight the recent literature regarding immune checkpoint inhibitor myocarditis.The use of immune checkpoint inhibitors, a promising form of immunotherapy, is rapidly increasing in oncology. These drugs have been recently found to cause a fulminant myocarditis associated with a high-case fatality rate ...
Jayant, Raikhelkar, Nir, Uriel
openaire +2 more sources
Checkpoint Inhibitor–Induced Colitis
American Journal of Gastroenterology, 2020Immune checkpoint inhibitors have revolutionized treatment and overall survival for several different types of cancer. Antibodies to cytotoxic T-lymphocyte-associated protein 4 and to programmed cell death protein 1 and its ligand enhance cytotoxic T-cell survival, thus augmenting antitumor action and consequently inducing immune-related adverse events,
Emanuelle, Bellaguarda, Stephen, Hanauer
openaire +2 more sources
Immune Checkpoint Inhibitors in Gliomas
Current Oncology Reports, 2017Malignant gliomas result in disproportionately high morbidity and mortality compared with other primary tumors, and progression of disease is inevitable. Novel therapies to improve outcomes are needed and immune checkpoint inhibitors hold significant promise.A limited body of preclinical evidence suggests that checkpoint inhibitors may be effective ...
Aaron C, Tan +2 more
openaire +2 more sources
Melanoma and Immune Checkpoint Inhibitors
Current Oncology Reports, 2018Prognosis of patients with advanced melanoma is dismal with a median overall survival of about 8 months and 5-year overall survival from a diagnosis of metastatic disease of roughly 10%. However, immune checkpoint inhibitors have brought indispensable benefits to melanoma patients.
Masutaka, Furue +5 more
openaire +2 more sources
Immune Checkpoint Inhibitor-associated Uveitis: Review of Treatments and Outcomes
Ocular Immunology and Inflammation, 2021Madeline Yung, Edmund Tsui
exaly
Checkpoint inhibitors in the emergency department
Emergency Medicine Australasia, 2019Caroline AE Bachmeier, Adam Morton
openaire +5 more sources